[go: up one dir, main page]

AR055271A1 - COMPOSITE OF CARBOXYLIC BIFENIL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE THIS LAST AND PROCESS TO PREPARE IT - Google Patents

COMPOSITE OF CARBOXYLIC BIFENIL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE THIS LAST AND PROCESS TO PREPARE IT

Info

Publication number
AR055271A1
AR055271A1 ARP050104182A ARP050104182A AR055271A1 AR 055271 A1 AR055271 A1 AR 055271A1 AR P050104182 A ARP050104182 A AR P050104182A AR P050104182 A ARP050104182 A AR P050104182A AR 055271 A1 AR055271 A1 AR 055271A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
hydrogen
independently
groups
Prior art date
Application number
ARP050104182A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR055271A1 publication Critical patent/AR055271A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/69—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

Compuestos del ácido bifenil carboxílico de la formula (1), en la que R1 se selecciona entre hidrogeno; alquilo C1-6 opcionalmente sustituido con hasta tres grupos seleccionados independientemente entre alcoxi C1-6, halogeno e hidroxi; cicloalquilo C3-7 opcionalmente sustituido independientemente con uno o más grupos de alquilo C1-6; un anillo arilo, heteroarilo, o heterociclilo cada uno opcionalmente sustituido, independientemente, con uno a tres grupos seleccionados entre R5 y R6; R2 es hidrogeno, alquilo C1-6 o un -(CH2)p-cicloalquiloC3-7 opcionalmente sustituido independientemente con uno o más grupos alquilo C1-6, o (CH2)mR1 y R2, junto con el átomo de nitrogeno al que están unidos, forman un anillo heterocíclico de cuatro a seis miembros opcionalmente sustituido, que contiene opcionalmente otro heteroátomo seleccionado entre O/N/S; R3 es halogeno o metilo; R4 es hidrogeno, alquilo C1-6, alquilo C1-6, halo-alquiloC1-4 sustituido o cicloalquilo C3-7; R5 es independientemente alquilo C1-6, OR4, -(CH2)p-cicloalquiloC3-7 opcionalmente sustituido independientemente con uno o más grupos alquilo C1-6, -CONR9R10, -NHCOR10, -SO2NHR9, -(CH2)qNHSO2R10, halogeno, CN, -(CH2)qNR11R12, y trifluorometilo; R6 es independientemente hidrogeno, alquilo C1-6, OR4, halogeno, trifluorometilo y -(CH2)qNR11R12; R8 se selecciona entre hidrogeno, alquilo C1-6, cicloalquilo C3-7 opcionalmente sustituido con uno o más grupos alquilo C1-6, OH, alquilo C1-6 opcionalmente sustituido con uno o más grupos hidroxilo, CONHR9, fenilo opcionalmente sustituido con R13 y/o R14, o un heteroarilo opcionalmente sustituido con R13 y/o R14; cada uno de R9 y R10 se selecciona independientemente entre hidrogeno y alquilo C1-6, o R9 y R10, junto con el átomo de nitrogeno al que están unidos, forman un anillo heterocíclico de cinco a seis miembros que opcionalmente contiene un heteroátomo adicional seleccionado entre oxígeno, azufre y N-R15, donde el anillo está opcionalmente sustituido con hasta dos grupos alquilo C1-6; R11 se selecciona entre hidrogeno, alquilo C1-6 y -(CH2)p-cicloalquiloC3-7 opcionalmente sustituido con uno o más grupos alquilo C1-6; R12 se selecciona entre hidrogeno y alquilo C1-6, o R11 y R12, junto con el átomo de nitrogeno al que están unidos, forman un anillo heterocíclico de cinco o seis miembros que opcionalmente contiene un heteroátomo adicional seleccionado entre oxígeno, azufre y N-R15; R13 se selecciona entre alquilo C1-6, alcoxi C1-6, -(CH2)p-cicloalquiloC3-7 opcionalmente sustituido con uno o más grupos alquilo C1-6, -CONR9R10, -NHCOR10, halogeno, CN, -(CH2)qNR11R12, trifluorometilo, fenilo opcionalmente sustituido independientemente con uno o más grupos R14, heterociclilo opcionalmente sustituido independientemente con uno o más grupos R14, y un heteroarilo opcionalmente sustituido independientemente con uno o más grupos R14; R14 se selecciona entre alquilo C1-6, alcoxi C1-6, halogeno, halo-alquiloC1-4 sustituido y NR11R12; R15 se selecciona entre hidrogeno y metilo; cada uno de X e Y se selecciona independientemente entre hidrogeno, metilo y halogeno; Z se selecciona entre -(CH2)sCOOR16, o -(CH2)sCONR16R17; R16 y R17 se seleccionan independientemente entre hidrogeno, alquilo C1-6 opcionalmente sustituido, -(CR20R21)vOR18, -(CR20R2I)vNR18R19, -(CR20R21)vNHSO2R18, -(CR20R21)vCONR18R19, -(CR20R21)vCOOR18, -(CR20R21)theteroarilo opcionalmente sustituido, -(CR20R21)tarilo opcionalmente sustituido, - (CR20R21)theterociclilo opcionalmente sustituido, -(CR20R21)tcicloalquiloC3-7 opcionalmente sustituido o -(CR20R21)tcicloalqueniloC3-7 opcionalmente sustituido; o R16 y R17, junto con el átomo de nitrogeno al que están unidos, forman un anillo de cinco a seis miembros opcionalmente sustituido que opcionalmente contiene al menos un heteroátomo adicional seleccionado entre oxígeno, azufre y N-R15; cada uno de R18 y R19 se selecciona independientemente entre hidrogeno y alquilo C1-6 opcionalmente sustituido con hasta dos grupos hidroxi; o R18 y R19, junto con el átomo de nitrogeno al que están unidos, forman un anillo de cinco a seis miembros, que opcionalmente contiene un heteroátomo adicional seleccionado entre oxígeno, azufre y N-R15, y donde el anillo está opcionalmente sustituido con hasta dos grupos seleccionados independientemente entre oxo, halogeno y alquilo C1-6; R20 y R21 se seleccionan independientemente entre hidrogeno o alquilo C1-4; m es 0 o un numero entero seleccionado entre 1, 2, 3 y 4; p es 0 o un numero entero seleccionado entre 1 y 2; q es 0 o un numero entero seleccionado entre 1, 2 y 3; r es 0 o el numero entero 1; s es 0 o un numero entero seleccionado entre 1, 2, 3 y 4; y t es 0 o un numero entero seleccionado entre 1, 2, 3, 4, 5 y 6; v es un numero entero seleccionado entre 1, 2, 3, 4, 5 y 6; o una sal farmacéuticamente aceptable o un derivado del mismo. Composicion farmacéutica que los comprende y su uso para la preparacion de dicha composicion farmacéutica util para el tratamiento de una afeccion o estado de enfermedad mediado por la actividad quinasa de p38 o mediado por citoquinas producidas por la actividad quinasa de p38. proceso para preparar dichos compuestos. Se aplican en el tratamiento de la inflamacion y enfermedades cronicas relacionadas.Biphenyl carboxylic acid compounds of the formula (1), wherein R 1 is selected from hydrogen; C1-6 alkyl optionally substituted with up to three groups independently selected from C1-6 alkoxy, halogen and hydroxy; C3-7 cycloalkyl optionally independently substituted with one or more C1-6 alkyl groups; an aryl, heteroaryl, or heterocyclyl ring each optionally substituted, independently, with one to three groups selected from R5 and R6; R2 is hydrogen, C1-6 alkyl or a - (CH2) p3-7 cycloalkyl optionally independently substituted with one or more C1-6 alkyl groups, or (CH2) mR1 and R2, together with the nitrogen atom to which they are attached , form an optionally substituted four to six membered heterocyclic ring, optionally containing another heteroatom selected from O / N / S; R3 is halogen or methyl; R4 is hydrogen, C1-6 alkyl, C1-6 alkyl, haloC1-4 substituted alkyl or C3-7 cycloalkyl; R5 is independently C1-6 alkyl, OR4, - (CH2) p3-7 cycloalkyl optionally independently substituted with one or more C1-6 alkyl groups, -CONR9R10, -NHCOR10, -SO2NHR9, - (CH2) qNHSO2R10, halogen, CN , - (CH2) qNR11R12, and trifluoromethyl; R6 is independently hydrogen, C1-6 alkyl, OR4, halogen, trifluoromethyl and - (CH2) qNR11R12; R8 is selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl optionally substituted with one or more C1-6 alkyl groups, OH, C1-6 alkyl optionally substituted with one or more hydroxyl groups, CONHR9, phenyl optionally substituted with R13 and / or R14, or a heteroaryl optionally substituted with R13 and / or R14; each of R9 and R10 is independently selected from hydrogen and C1-6 alkyl, or R9 and R10, together with the nitrogen atom to which they are attached, form a five to six membered heterocyclic ring that optionally contains an additional heteroatom selected from oxygen, sulfur and N-R15, where the ring is optionally substituted with up to two C1-6 alkyl groups; R11 is selected from hydrogen, C1-6 alkyl and - (CH2) p3-7 cycloalkyl optionally substituted with one or more C1-6 alkyl groups; R12 is selected from hydrogen and C1-6 alkyl, or R11 and R12, together with the nitrogen atom to which they are attached, form a five or six membered heterocyclic ring that optionally contains an additional heteroatom selected from oxygen, sulfur and N- R15; R13 is selected from C1-6 alkyl, C1-6 alkoxy, - (CH2) p3-7 cycloalkyl optionally substituted with one or more C1-6 alkyl groups, -CONR9R10, -NHCOR10, halogen, CN, - (CH2) qNR11R12 , trifluoromethyl, phenyl optionally independently substituted with one or more R14 groups, heterocyclyl optionally substituted independently with one or more R14 groups, and a heteroaryl optionally substituted independently with one or more R14 groups; R14 is selected from C1-6 alkyl, C1-6 alkoxy, halogen, halo-substituted C1-4 alkyl and NR11R12; R15 is selected from hydrogen and methyl; each of X and Y is independently selected from hydrogen, methyl and halogen; Z is selected from - (CH2) sCOOR16, or - (CH2) sCONR16R17; R16 and R17 are independently selected from hydrogen, optionally substituted C1-6 alkyl, - (CR20R21) vOR18, - (CR20R2I) vNR18R19, - (CR20R21) vNHSO2R18, - (CR20R21) vCONR18R19, - (CR20R21) vCOOR18, - (CR20R21) optionally substituted theteroaryl, - (CR20R21) optionally substituted taryl, - (CR20R21) optionally substituted theterocyclyl, - ((CR20R21) optionally substituted C3-7 cycloalkyl or - (CR20R21) optionally substituted C3-7 tcycloalkenyl; or R16 and R17, together with the nitrogen atom to which they are attached, form an optionally substituted five to six member ring that optionally contains at least one additional heteroatom selected from oxygen, sulfur and N-R15; each of R18 and R19 is independently selected from hydrogen and C1-6 alkyl optionally substituted with up to two hydroxy groups; or R18 and R19, together with the nitrogen atom to which they are attached, form a five to six member ring, which optionally contains an additional heteroatom selected from oxygen, sulfur and N-R15, and where the ring is optionally substituted with up to two groups independently selected from oxo, halogen and C1-6 alkyl; R20 and R21 are independently selected from hydrogen or C1-4 alkyl; m is 0 or an integer selected from 1, 2, 3 and 4; p is 0 or an integer selected between 1 and 2; q is 0 or an integer selected from 1, 2 and 3; r is 0 or the whole number 1; s is 0 or an integer selected from 1, 2, 3 and 4; and t is 0 or an integer selected from 1, 2, 3, 4, 5 and 6; v is an integer selected from 1, 2, 3, 4, 5 and 6; or a pharmaceutically acceptable salt or derivative thereof. Pharmaceutical composition comprising them and their use for the preparation of said pharmaceutical composition useful for the treatment of a disease or disease condition mediated by the kinase activity of p38 or mediated by cytokines produced by the kinase activity of p38. process to prepare said compounds. They are applied in the treatment of inflammation and related chronic diseases.

ARP050104182A 2004-10-05 2005-10-03 COMPOSITE OF CARBOXYLIC BIFENIL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE THIS LAST AND PROCESS TO PREPARE IT AR055271A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61606504P 2004-10-05 2004-10-05
US71972905P 2005-09-22 2005-09-22

Publications (1)

Publication Number Publication Date
AR055271A1 true AR055271A1 (en) 2007-08-15

Family

ID=37087462

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104182A AR055271A1 (en) 2004-10-05 2005-10-03 COMPOSITE OF CARBOXYLIC BIFENIL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE THIS LAST AND PROCESS TO PREPARE IT

Country Status (6)

Country Link
EP (1) EP1805132A4 (en)
JP (1) JP2008515898A (en)
AR (1) AR055271A1 (en)
PE (1) PE20060493A1 (en)
TW (1) TW200628153A (en)
WO (1) WO2006110173A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
CN104281006B (en) 2006-11-02 2019-01-22 三菱瓦斯化学株式会社 Radiation Sensitive Composition
JP5446118B2 (en) * 2007-04-23 2014-03-19 三菱瓦斯化学株式会社 Radiation sensitive composition
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
RU2456266C1 (en) * 2011-04-06 2012-07-20 Максим Эдуардович Запольский 4,4'-biphenylamide derivatives showing pharmacological activity, and based drug preparations
WO2016029216A2 (en) * 2014-08-22 2016-02-25 Biocryst Pharmaceuticals, Inc. Method for producing amidine derivatives
CN106554314B (en) * 2015-09-30 2021-07-27 石药集团中奇制药技术（石家庄）有限公司 benzamide derivatives
KR20200067170A (en) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 P38 kinase inhibitors that reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138451A (en) * 1979-04-03 1982-12-28 Ikuo Ueda 2-imidazoline derivatives, process for the preparation thereof and the pharmaceutical composition of the same
KR100340273B1 (en) * 1997-10-14 2002-06-14 야마모토 카즈모토 Biphenyl-5-Alkanoic Acid Derivatives and Use thereof
KR20010082515A (en) * 1998-02-17 2001-08-30 우에노 도시오 Amidino derivatives and drugs containing the same as the active ingredient
CA2358047A1 (en) * 1998-12-24 2000-07-06 Francis A. Volz Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds
GB0124928D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
WO2006110173A2 (en) 2006-10-19
EP1805132A4 (en) 2010-01-20
TW200628153A (en) 2006-08-16
WO2006110173A3 (en) 2006-11-23
PE20060493A1 (en) 2006-09-03
JP2008515898A (en) 2008-05-15
EP1805132A2 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
AR127309A2 (en) PYRDAZINONE DERIVATIVES
AR081994A1 (en) DERIVATIVES OF [1,8] NAFTIRIDINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME FOR THE TREATMENT OF DISEASES INDICATED BY KINASES, IN PARTICULAR DIFFERENT TYPES OF CANCERES
AR055271A1 (en) COMPOSITE OF CARBOXYLIC BIFENIL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE THIS LAST AND PROCESS TO PREPARE IT
AR057104A1 (en) DIAMINOPIRIMIDINS AS MODULATORS OF P2 X3 AND P2X2 / 3 AND PHARMACEUTICAL COMPOSITION
AR044045A1 (en) COMPOSITE OF PIPERIDINCARBONILPIPERAZINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PROCEDURE FOR PREPARATION
AR077143A1 (en) INSECTICIDE COMPOUNDS
AR084768A1 (en) MODULATORS OF THE COMPLEMENT PATH AND USES OF THE SAME
AR061374A1 (en) DERIVATIVES OF ANTRANILIC ACID DIAMIDES WITH ITS HETEROAROMATIC AND HETEROCICLIC SUBSTITUTES
AR035235A1 (en) HETEROCICLILOXI DERIVATIVES -, - TIOXI- AND -AMINOBENZAZOL AS 5-HYDROXITRIPTAMINE-6 LINES, A PROCEDURE FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR079231A1 (en) IMIDAZOQUINOLINE DERIVATIVES
RU2018121499A (en) HYPOXANTINES AS UBIQUITINE-SPECIFIC PROTEASE INHIBITORS 1
AR078168A1 (en) DERIVATIVES OF PIPERIDINS AND PIPERAZINS, PROCESSES TO PREPARE THEM AND THEIR USES AS MODULATORS OF GPR119
AR049956A1 (en) DERIVATIVES OF 1,3 - OXAZOLIDIN - 2 - ONA AS CETP INHIBITORS AND LAD-C LEVEL ELEVATORS; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ATEROSCLEROSIS.
AR079224A1 (en) INSECTICIDE COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES
AR110139A1 (en) MONO AND SPIROCYCLES COMPOUNDS CONTAINING CYCLLOBUTAN AND AZETIDINE AS INHIBITORS OF INTEGRINE AV
AR086546A1 (en) DERIVATIVES OF 7H-PURIN-8 (9H) -ONA AS JAK INHIBITORS
AR057769A1 (en) PIRAZOLO PIRIMIDINAS AS MAP QUINASA P38 INHIBITORS, METHODS FOR USE AND PHARMACEUTICAL COMPOSITIONS
AR076117A1 (en) DERIVATIVES OF PIRIMIDIN -4- ILPROPANODINITRILO, PROCEDURE FOR PREPARATION, AS WELL AS ITS USE IN QUALITY OF HERBICIDES AND AGENTS REGULATING GROWTH OF PLANTS
AR084308A1 (en) INSECTICIDE COMPOUNDS DERIVED FROM TRIAZOL
AR034203A1 (en) DERIVATIVES OF 1-ARIL- OR 1-ALQUILSULFONILBENZAZOL AS LIGANDS OF 5-HYDROXITRIPTAMINE-6, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR064463A1 (en) PYRIMIDINPIRAZOLES REPLACED, METHODS FOR THEIR PREPARATION, ITS USE IN THE FIGHTING OF PESTS, PROCEDURES TO COMBAT ANIMAL PESTS AND A PROCESS TO PREPARE AGROCHEMICAL COMPOSITIONS THAT EMPLOY.
NO20072371L (en) Kinuclidine derivatives and their use as muscarinic M3 receptor antagonists
MA26904A1 (en) AMINOALKYL 1-LACTAMS SUBSTITUTED AND THEIR USE AS ANTAGONISTS OF THE MUSCARINIC RECEPTOR.
AR065891A1 (en) DERIVATIVES OF PYRIDINE AND PYRIMIDINE AS ANTAGONISTS OF MGLUR2
AR083525A1 (en) DERIVATIVES OF PICOLINIC ACID REPLACED WITH HETEROCICLES, METHOD TO PREPARE THEM, USE OF THE SAME AS HERBICIDES AND HERBICIDE COMPOSITIONS CONTAINING THEM

Legal Events

Date Code Title Description
FB Suspension of granting procedure